Strategy may bolster blood cancer therapy and move HIV research closer to a cure.
Albert Einstein College of Medicine press release
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments. Their findings, published in Science Advances, describe a manufacturing approach that, compared to the existing process, generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection in mouse models.
“Our goal was to engineer therapeutic immune cells so they would not only be powerful killers but also long-lived and capable of self-renewal, to markedly extend their effectiveness after infusion into patients,” said senior author Harris Goldstein, M.D., professor of pediatrics and of microbiology & immunology and director of the Einstein-Rockefeller-CUNY-Mount Sinai Center for AIDS Research. “By improving how we generate CAR-T cells, a treatment that acts as a ‘living drug,’ we would prolong their functional activity and prevent disease relapse after their potency wanes.” Dr. Goldstein also holds the Charles Michael Chair in Autoimmune Diseases at Einstein.
Read the full press release here.
Source : Albert Einstein College of Medicine
Related HIV and Co-Infections News
-
NIH-funded breakthrough shrinks CRISPR for precision delivery in the body
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
UNC School of Medicine: Researchers demonstrate drug’s effectiveness in drawing out dormant HIV from immune cells
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.